FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, namely to DNA construct for expression of genes in eukaryotic cells, where construct is linear DNA with open chain, containing promoter sequence, coding sequence and termination signal, where construct contains at least one L-DNA nucleotide and where at least one L-DNA nucleotide is located in last 2-5 nucleotides of 5′- and/or 3′- end, as well as to pharmaceutical composition containing it. Invention also relates to method of stable or transient transfection of human, animal or eukaryotic cells, which involves incubation of human, animal or eukaryotic cells with said DNA construct.
EFFECT: invention enables efficient stable or transient transfection of human, animal or eukaryotic cells.
10 cl, 7 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
NON-CODING IMMUNOMODULATORY DNA CONSTRUCT | 2011 |
|
RU2583291C2 |
ALLOGENEIC ANTITUMOR THERAPEUTIC MEDICATION | 2004 |
|
RU2354694C2 |
ARTIFICIAL NUCLEIC ACID MOLECULES | 2013 |
|
RU2651498C2 |
TREATMENT OF HBV INFECTION | 2011 |
|
RU2620966C2 |
COVALENTLY CLOSED NON-CODING IMMUNOMODULATORY DNA CONSTRUCT | 2015 |
|
RU2668387C2 |
MULTI-CHAIN CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF | 2013 |
|
RU2663725C2 |
METHOD FOR CREATION OF T-CELLS SUITABLE FOR ALLOGENEIC TRANSPLANTATION | 2015 |
|
RU2752933C2 |
PaCas9 NUCLEASE | 2018 |
|
RU2706298C1 |
CELL TARGETING MEDIATED BY CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2783316C2 |
THERAPEUTIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | 2015 |
|
RU2711147C2 |
Authors
Dates
2016-12-10—Published
2011-12-23—Filed